KVUE
Kenvue Inc.Evidence as of 2026-09-03Overview · Kenvue Inc.
Kenvue Inc. operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, and other products under the Tylenol, Nicorette, and Zyrtec brands. The Skin Health and Beauty segment provides face and body care, hair care, and sun and…
Management team
- Mr. Matthew Orlando · General CounselFind on LinkedIn
- Ms. Tina Romani · Head of Investor RelationsFind on LinkedIn
- Ms. Meredith Stevens · Chief Operations OfficerFind on LinkedIn
- Ms. Ellie Bing Xie · Group President of Asia PacificFind on LinkedIn
Start your 7-day free trial to see the full management team.
Links open LinkedIn searches, not verified profiles. Team data from our market-data vendor's company profile.
Moneyta sentiment
Where the published evidence leans after the desk debated it — not a rating or a recommendation.
+0.0 on a −2 to +2 scale — was −0.0 before the debate changed the read.
What builds the score
Solid bars are analyst rubric scores; faded bars are computed directly from data. Claims dropped in debate count for nothing; weakened claims count at half weight.
Editor's note
Written after the debate settled — the rest of the page is the evidence behind it.
Evidence balance: Mixed. The surviving claims establish that reported revenue edged up from $3,909,000,000 in fiscal Q1 2026 (fiscal quarter ended 2026-05-01) to $3,955,000,000 in fiscal Q2 2026 (fiscal quarter ended 2026-07-31), a quarter-over-quarter increase of $46,000,000. Gross profit was essentially flat at about $2,302,000,000 in Q1 2026 and $2,301,000,000 in Q2 2026, while operating income compressed from $767,000,000 to $699,000,000 (a decline of $68,000,000), and net income fell modestly from $474,000,000 to $456,000,000 with diluted EPS moving from $0.25 to $0.24.
Capital structure and cash-flow signals in the packet are explicit but limited: weighted-average diluted shares were roughly 1,922,000,000–1,923,000,000 across the two quarters, reported common shares outstanding rose slightly to 1,920,773,467 as of 31 July 2026, and the company reported $63,000,000 of common-stock repurchases in the quarter ended 29 March 2026. Market evidence shows mixed price action and income characteristics — dividend yield of 4.35% (92nd percentile), modest positive short-term momentum but negative twelve‑month momentum, a golden-cross in place with price slightly above the 50‑day and 200‑day SMAs, low correlation and low beta to SPY, and mid-teens valuation multiples (P/FCF ~ 24.86, EV/EBITDA ~ 12.94, P/E ~ 20.79).
How this note was made
every stage ran before the note was writtenAnalyst desk
Mercer, Oakes, Nash, Ellis, Yates, Talbot and Archer. The desk: named AI agents, not people. Each reads one slice of the evidence and nothing else — no outside knowledge, no browsing — so every finding traces to a source you can open.
Reads the XBRL figures companies file with the SEC — revenue, margins, income, debt and share count, quarter by quarter — and reports which way the trend is running.
Revenue was $3,909,000,000 in fiscal Q1 2026, ended 31 March 2026, and $3,955,000,000 in fiscal Q2 2026, ended 28 June 2026 (a quarter-over-quarter increase of $46,000,000).
XBRL companyfacts · 0001944048-26-000098Gross profit was essentially flat between the two most recent quarters: $2,302,000,000 in fiscal Q1 2026, ended 31 March 2026, and $2,301,000,000 in fiscal Q2 2026, ended 28 June 2026.
XBRL companyfacts · 0001944048-26-000142Reads the filings themselves, above all the year-over-year diff of Item 1A risk factors: which risks a company added, dropped or quietly reworded since its last annual report.
Nothing in this slice of the evidence rose to a claim — a quiet read, which itself is information.
Which filings the desk reads
The desk reads the annual 10-K in full — its risk factors, and how they changed since last year. Quarterly 10-Qs and event filings (8-Ks, insider Form 4s) are listed for context but not read line by line: the 10-K is where the material risk disclosures live. A brand-new company, or one we have only just begun tracking, may have no annual report on file yet — its risk analysis fills in once that lands.
Reads the signal panel above — momentum, volatility, drawdown, relative strength and beta — and ranks each against the whole research universe rather than judging it in isolation.
Three-month momentum is +14.9% as of 2026-09-02, while six-month momentum is +7.6%.
Moneyta signal set · 2026-09-02weakened in debateTwelve-month momentum (12_1) is -5.3% and ranks in the 24th percentile of the 547-stock research universe as of 2026-09-02.
Moneyta signal set · 2026-09-02weakened in debateReads which funds hold the name and at what weight, plus insider Form 4 filings, to show the exposure you may already carry through index funds.
As of 2026-09-02T13:45:47.228469+00:00, KVUE appears as a holding in the ETF with symbol IVV at a weight of 0.06% of that fund.
ETF constituents · market dataThe reported 0.06% weight indicates a relatively small position within that single ETF holding entry.
ETF constituents · market dataReads recent headlines that are genuinely about this company, ignoring rating chatter and market-wide stories. Findings argue in the debate but never move the sentiment score.
A product-focused article reports Kenvue's Zyrtec brand launched Zyrtec Allergen Shield Spray, described as a drug-free nasal mist that forms a protective gel barrier for up to six hours.
News · simplywall.st · 2026-08-25A filing-based headline reports the Canada Pension Plan Investment Board acquired 3,919,153 shares of Kenvue in the second quarter.
News · thelincolnianonline.com · 2026-08-27Reads parsed Forms 3/4/5 — who bought or sold, at what size, and whether a 10b5-1 plan was involved. Flags clustered open-market officer buying; treats plan sales as routine and never counts a fund or 10%-holder as an officer.
No insider transactions on file in the trailing 180 days.
Reads the implied-expectations math built from the company's own filings (the growth rate today's price would justify, and the multiples beside it) and argues whether the market's bar looks high or low for this business. Never turns the math into a target.
The model reports an implied free cash flow (FCF) growth rate of 14.36% that today's price would justify under the stated discount and terminal assumptions.
Valuation inputs · SEC XBRL + stored EOD closePrice-to-free-cash-flow (P/FCF, trailing twelve months) is 24.86 at the reported price of 19.13 and the stated FCF TTM of $1,480,000,000.
Valuation inputs · SEC XBRL + stored EOD closeDebate and risk review
A bull and a bear contest the claims and the chair rules on each; the risk review stress-tests what survived.
A bull and a bear argue the analysts' claims across two rounds, then a chair rules on each one. Only what survives feeds the score — the argument is shown, not hidden, so you can judge the reasoning yourself.
Several pieces of filed and market-evidence jointly support a favorable read. Quarterly revenue ticked up quarter-over-quarter and gross profit was essentially flat (both from SEC filings), indicating topline resilience while cost of goods sold remained steady. Market signals show improving short-term momentum (+14.9% three-month), a high trailing dividend yield (4.35%, 92nd percentile), and technicals with price above both the 50- and 200-day SMAs after a 73-day golden cross; multiple institutional filings also report new/added positions, which together strengthen the constructive market-interest case. The cited operating-income and EPS declines are present in filings but are modest in absolute terms relative to reported revenue and gross-profit stability; therefore, the combined evidence leans toward a favorable operational and market backdrop rather than a clear deterioration.
Chair's verdict, claim by claim
Fragility · computed, not argued
balanced0.36
27 surviving claims rest on 12 distinct sources; the heaviest analyst carries 26% of them, and 96% of what the desk raised survived the debate.
The surviving set is reasonably informative but not rock-solid: 27 claims draw on a modestly small pool of 12 distinct sources, so individual sources can move the balance. The largest analyst carrying 26% of claims and the very high (96%) debate survival rate imply low internal pushback and some analyst-concentration risk — treat the read as useful but somewhat fragile to new filings or independent contradictory evidence.
Peer context · computed, not argued
12-1 momentum ranks 2nd of 2 in Household & Personal Products (as of 2026-09-02).
6-month relative strength ranks 1st of 2 in Household & Personal Products (as of 2026-09-02).
90-day volatility ranks 1st of 2 in Household & Personal Products (as of 2026-09-02).
dividend yield ranks 1st of 2 in Household & Personal Products (as of 2026-09-02).
Disconfirming evidence · base rates · falsifiers
Context
Outside consensus, and where this name already sits in your own portfolio.
Third-party consensus shown for context. It never enters Moneyta sentiment — when the two diverge, the debate above is where the why lives.
What this was built from
Every figure on this page traces to one of these. The desk reads only what is listed here — no outside knowledge, no browsing — and each card shows who read it and what it contributed to the score.
11 filings· 2 cited
SEC XBRL filings
Quarterly figures as filed with the SEC, read straight from EDGAR's structured data — not retyped or estimated.
Read by Mercer−0.3 to the score
1 signal set
Moneyta signal set
Computed from our own end-of-day price history and ranked against the whole research universe. No AI involved.
Read by Nash+0.3 to the score
1 holdings record
Fund holdings
Which funds hold this name and at what weight, plus insider Form 4 filings.
Read by Ellis+0.0 to the score
8 headlines· 2 cited
News coverage
Recent headlines about this company, rating chatter excluded and nothing published after the report date.
Read by Yatesnothing survived
1 computation
Valuation inputs
TTM cash-flow figures from the company's own XBRL filings, priced with the stored closing price. Implied growth and multiples only; no fair-value dollar figure reaches the desk, by design.
Read by Archercontext only
1 record· 0 cited
Company profile
Sector, industry and company details.
Read means we pulled and handed it to an analyst; cited means a claim on this page points at it. Reading twelve quarters to state one trend is normal — the gap is shown rather than hidden.
Written by AI, checked against sources
The analysts, the bull–bear debate and the editor's note are AI agents reading only the evidence listed on this page. They can misread a filing or a headline, which is why every claim cites a source you can open and check yourself. The sentiment score is arithmetic over the claims that survived the debate, not a language model's opinion.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations. Past patterns do not indicate future results.
Get this for the tickers you actually hold
Plus the one thing no sample can show: how each name correlates with your portfolio, and what hides inside your funds.
The full terminal on KVUE Gold
Who holds it, who's buying, what the Street thinks: live behind the lock, updated as filings land.
Institutional holders
Net institutional flow, Q/Q
Largest holder position
Insider buys, 90 days
Clustered insider value
Street target range
The real figures are for members. Educational analysis, not advice.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations.